1257628-64-0
1257628-64-0 structure
- Name: GZD856
- Chemical Name: GZD856
- CAS Number: 1257628-64-0
- Molecular Formula: C29H27F3N6O
- Molecular Weight: 532.56
- Catalog: Signaling Pathways Protein Tyrosine Kinase/RTK PDGFR
- Create Date: 2019-02-23 10:56:22
- Modify Date: 2024-01-14 19:51:43
-
GZD856 is a novel PDGFRα/β inhibitor with IC50s of 68.6 and 136.6 nM, respectively. Anti-lung cancer activities[1].
| Name | GZD856 |
|---|
| Description | GZD856 is a novel PDGFRα/β inhibitor with IC50s of 68.6 and 136.6 nM, respectively. Anti-lung cancer activities[1]. |
|---|---|
| Related Catalog | |
| Target |
IC50: 68.6 nM (PDGFRα), 136.6 nM (PDGFRβ)[1] |
| In Vitro | GZD856 (0.0032-10 μM) exerts antiproliferative activity against a panel of lung cancer cells[1]. GZD856 shows dose-dependent inhibition of PDGFRα and PDGFRβ phosphorylation in H1703 and A549 cells, respectively. The activation of downstream AKT (phosphorylation of S473 but not T308), ERK1/2 and STAT3 is also observed after exposure to GZD856, with no obvious effects on total protein levels[1]. GZD856 induces dose-dependent G0/G1 phase arrest and apoptosis in H1703 cells but not in A549 cells[1]. |
| In Vivo | GZD856 (10 and 30 mg/kg/day) displays good in vivo antitumor activity in both H1703 and A549 lung cancer models[1]. GZD856 exhibits dose-dependent suppression of PDGFRα and PDGFRβ activation and downstream signaling in H1703 and A549 tumor tissues[1]. GZD856 displays promising in vivo therapeutic effects on PDGFRα-/PDGFRβ+ A549 cancer cells in a Luc orthotopic model, inhibiting both tumor growth and tumor metastasis[1]. |
| References |
| Molecular Formula | C29H27F3N6O |
|---|---|
| Molecular Weight | 532.56 |